Change in 6‐minute walking distance · patients with chronic obstructive pulmonary disease
1 finding from 1 review
no estimate extracted
99 participants
Moderate
Exercise capacity · patients with chronic obstructive pulmonary disease
1 finding from 1 review
no estimate extracted
30 participants
High
Exercise capacity (change from baseline) · patients with chronic obstructive pulmonary disease
1 finding from 1 review
no estimate extracted
30 participants
High
Quality of life St George's Respiratory Questionnaire (SGRQ) score · patients with chronic obstructive pulmonary disease
1 finding from 1 review
no estimate extracted
19 participants
Low
Change in 6‐minute walking distance · patients with chronic obstructive pulmonary disease
1 finding from 1 review
no estimate extracted
62 participants
Moderate
Exercise capacity · patients with chronic obstructive pulmonary disease
1 finding from 1 review
no estimate extracted
59 participants
Low
Exercise capacity (change from baseline) · patients with chronic obstructive pulmonary disease
1 finding from 1 review
no estimate extracted
59 participants
Moderate
QoL · patients with chronic obstructive pulmonary disease
1 finding from 1 review
no estimate extracted
60 participants
Low
Change in weight (kg) · patients with chronic obstructive pulmonary disease
1 finding from 1 review
no estimate extracted
59 participants
Moderate
Lung function: FEV1 mL (change from baseline) · participants with stable stage 3 COPD, smokers and ex‐smokers with a minimum pack‐year history of 20
1 finding from 1 review
Pneumonia · participants with stable stage 2 and 3 COPD (mainly FEV1 49 ± 12% predicted), ex‐smokers (majority), smokers and non‐smokers
1 finding from 1 review
Exacerbations · participants with stable stage 2 and 3 COPD (mainly FEV1 49 ± 12% predicted), ex‐smokers (majority), smokers and non‐smokers
1 finding from 1 review
Symptoms of dyspnoea · participants with stable stage 2 and 3 COPD (mainly FEV1 49 ± 12% predicted), ex‐smokers (majority), smokers and non‐smokers
1 finding from 1 review
Adverse events: candidiasis · participants with stable stage 2 and 3 COPD (mainly FEV1 49 ± 12% predicted), ex‐smokers (majority), smokers and non‐smokers
It is very uncertain whether beclometasone changes adverse events: candidiasis compared with placebo (very low certainty).
1 finding from 1 review
Withdrawal (all‐cause) · participants with stable stage 2 and 3 COPD (mainly FEV1 49 ± 12% predicted), ex‐smokers (majority), smokers and non‐smokers
Beclometasone showed no clear difference in withdrawal (all‐cause) compared with placebo (low certainty).
1 finding from 1 review
Mortality (all‐cause) (dichotomous Peto method) · participants with stable stage 3 COPD, smokers and ex‐smokers with a minimum pack‐year history of 20
It is very uncertain whether beclometasone/LABA changes mortality (all‐cause) (dichotomous Peto method) compared with LABA (very low certainty).
1 finding from 1 review
Pneumonia · participants with stable stage 3 COPD, smokers and ex‐smokers with a minimum pack‐year history of 20
Beclometasone/LABA showed no clear difference in pneumonia: participants with at least one (dichotomous Peto odds… compared with LABA (low certainty).
1 finding from 1 review
Exacerbations · participants with stable stage 3 COPD, smokers and ex‐smokers with a minimum pack‐year history of 20
Beclometasone/LABA showed no clear difference in exacerbations: participants with at least one (dichotomous) compared with LABA (moderate certainty).
1 finding from 1 review
Change in quality of life: SGRQ Scale: 0 to 100 · participants with stable stage 3 COPD, smokers and ex‐smokers with a minimum pack‐year history of 20
1 finding from 1 review
Adverse events: candidiasis · participants with stable stage 3 COPD, smokers and ex‐smokers with a minimum pack‐year history of 20
1 finding from 1 review